As Gilead’s stock price gets blitzed after a series of pratfalls, why is Dan O’Day getting a small raise?

Over the past year, Gilead has been subjected to one nasty setback after the next. But it hasn’t even dented Daniel O’Day’s pay package.

True, his base pay is down a tad, from $1.7 to $1.65 million, according to the SEC filing. The non-equity incentive comp also dipped. But those stock awards and options jumped by more than $1.5 million in value, allowing the Roche vet to see his total compensation edge up from $19 million to $19.2 million, give or take a few bucks.

This article is for premium subscribers only

Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.

UPGRADE

TRENDING NOW

As Gilead’s stock price gets blitzed after a series of pratfalls, why is Dan O’Day getting a small raise?

This article is for premium subscribers only

J&J's AI head jumps to Recursion; Doug Williams resigns as Sana's R&D chief

Rare neuro disorder offers new area for competition, analysts say: #AAN24

CSL Vifor proposes a marketing campaign to settle European Commission investigation

Vertex, Alpine’s IgAN drug has Humira-like potential. But not all indications are created equal

Takeda wins label expansion for subcutaneous Entyvio, creating 'flexibility' for Crohn's patients

Bruker to acquire troubled spatial biology company NanoString for $392M

As Gilead’s stock price gets blitzed af­ter a se­ries of prat­falls, why is Dan O’Day get­ting a small raise?

This article is for premium subscribers only

more like this

J&J's AI head jumps to Re­cur­sion; Doug Williams re­signs as Sana's R&D chief

Rare neu­ro dis­or­der of­fers new area for com­pe­ti­tion, an­a­lysts say: #AAN24

CSL Vi­for pro­pos­es a mar­ket­ing cam­paign to set­tle Eu­ro­pean Com­mis­sion in­ves­ti­ga­tion

Ver­tex, Alpine’s IgAN drug has Hu­mi­ra-like po­ten­tial. But not all in­di­ca­tions are cre­at­ed equal

Take­da wins la­bel ex­pan­sion for sub­cu­ta­neous En­tyvio, cre­at­ing 'flex­i­bil­i­ty' for Crohn's pa­tients

Bruk­er to ac­quire trou­bled spa­tial bi­ol­o­gy com­pa­ny NanoS­tring for $392M

As Gilead’s stock price gets blitzed after a series of pratfalls, why is Dan O’Day getting a small raise?

J&J's AI head jumps to Recursion; Doug Williams resigns as Sana's R&D chief

Rare neuro disorder offers new area for competition, analysts say: #AAN24

CSL Vifor proposes a marketing campaign to settle European Commission investigation

Vertex, Alpine’s IgAN drug has Humira-like potential. But not all indications are created equal

Takeda wins label expansion for subcutaneous Entyvio, creating 'flexibility' for Crohn's patients

Bruker to acquire troubled spatial biology company NanoString for $392M